Comparative Pharmacology
Head-to-head clinical analysis: METHYLIN versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLIN versus QUILLIVANT XR.
METHYLIN vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant. It blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
10 mg orally twice daily, administered 4-6 hours apart; doses may be adjusted in 5-10 mg increments weekly up to 60 mg/day.
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
2-4 hours (short elimination half-life, requiring multiple daily dosing; immediate-release: 3-4 hours, extended-release: 3-6 hours)
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Renal: 90% (mainly as metabolites, 30-50% as unchanged drug); fecal: <1%
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant